New Drug Dostarlimab Achieves 100% Cure Rate in Advanced Rectal Cancer Trial
TL;DR Summary
GSK's new drug Jemperli (dostarlimab) achieved a 100% cure rate in a phase 2 trial for mismatch repair deficient (dMMR) locally advanced rectal cancer, showing no evidence of remaining tumors in 42 patients. The drug, which enhances the immune system's ability to detect and kill cancer cells, could revolutionize treatment by eliminating the need for chemotherapy and surgery. Further studies are ongoing to confirm its efficacy in other colorectal cancers.
- New bowel tumor drug helped cure cancer in 100% of cases BGR
- Drug that ‘melts away’ tumours hailed as ‘gamechanger’ for some bowel cancer patients The Guardian
- Dostarlimab 2 for 2: Snagging 100% Clinical CR in dMMR Locally Advanced Rectal Cancer OncLive
- GSK's Jemperli shows potential in Phase II rectal cancer trial Clinical Trials Arena
- Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
13
Time Saved
2 min
vs 3 min read
Condensed
87%
535 → 70 words
Want the full story? Read the original article
Read on BGR